Thursday, November 21, 2024
HomeLaw firmsDeals and TransactionsSenores Pharmaceuticals Files IPO with SEBI, Targets INR 500 billion

Senores Pharmaceuticals Files IPO with SEBI, Targets INR 500 billion

JSA Advises Equirus Capital, Ambit Private Limited, and Nuvama Wealth Management on Senores Pharmaceuticals‘ INR 5 Billion Initial Public Offering

The transaction team included Lead Partner Arka Mookerjee, Partner Siddhartha Desai, Senior Associate Akash Joshi, Associates  Govind RoyAnvita SinhaReshmi Prabhakar and Ankesh Kumar.

The proceeds from the fresh issuance will be used to establish a manufacturing facility for sterile injections at its Atlanta location, cover the working capital needs of the company and its subsidiaries, support growth through acquisitions and other strategic initiatives, and settle existing debt. Additionally, a portion of the funds will be allocated for general corporate purposes.

Senores Pharmaceuticals focuses on identifying, developing, and manufacturing a broad range of specialty and complex pharmaceutical products. As of March this year, the company had introduced 54 products across major therapeutic areas, including antibiotics, anti-bacterial agents, anti-fungal treatments, and blood line products.

Share your news, articles, deals, columns, or press releases with us! Click the link to submit and join our platform today.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Today's Headlines